Subsequent events

12 Months Ended

Mar. 31, 2023

Subsequent Events [Abstract]

Subsequent events

30. Subsequent events

In April 2023, the Company and Nanjing Animal Pharmaceutical signed the Convertible Debt Release Agreement, in which Nanjing Animal Pharmaceutical would redeem part of the convertible debts from the Company. According to the agreement, Nanjing Animal Pharmaceutical repaid the Company the principal amount of RMB6 million, interest of RMB0.84 million, and an additional compensation of RMB1.06 million in April 2023.